NRF2 — Nuclear Factor Erythroid 2-Related Factor 2

Introduction

Nrf2 (Nuclear Factor Erythroid 2 Related Factor 2) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Pathway / Mechanism Diagram

graph TD
    A["Normal Conditions"] --> B["Keap1 Binds NRF2"]
    B --> C["NRF2 Ubiquitination"]
    C --> D["Proteasomal Degradation"]
    E["Oxidative Stress"] --> F["Keap1 Cysteine Modification"]
    F --> G["NRF2 Release"]
    G --> H["Nuclear Translocation"]
    H --> I["ARE Binding"]
    I --> J["HO-1: Heme Detoxification"]
    I --> K["NQO1: Quinone Detoxification"]
    I --> L["GST: Glutathione Conjugation"]
    I --> M["Catalase, SOD"]
    J --> N["Neuroprotection"]
    K --> N
    L --> N
    M --> N
    O["NRF2 Decline in Aging"] --> P["Reduced Antioxidant Defense"]
    P --> Q["Oxidative Neurodegeneration"]
    style N fill:#1b5e20,color:#e0e0e0
    style Q fill:#ef5350,color:#e0e0e0
    style H fill:#006494,color:#e0e0e0

Overview

NRF2 (Nuclear factor erythroid 2-related factor 2), encoded by the NFE2L2 gene on chromosome 2q31.2, is the master transcriptional regulator of the cellular antioxidant and cytoprotective response. NRF2 orchestrates the expression of over 250 genes containing antioxidant response elements (AREs) in their promoters, encoding a broad battery of phase II detoxification enzymes, antioxidant proteins, and anti-inflammatory mediators ^{2Citation2019 · DOI 10.1038/s41573-018-0008-xOpen reference}8^{2Citation2019 · DOI 10.1038/s41573-018-0008-xOpen reference}9. Under basal conditions, NRF2 is kept at low levels through ubiquitin-proteasome degradation mediated by its negative regulator Keap1 (Kelch-like ECH-associated protein 1). Upon oxidative-stress, electrophilic signals, or therapeutic activators, NRF2 dissociates from Keap1, translocates to the nucleus, and drives transcription of cytoprotective genes ^{3Citation2016 · DOI 10.1080/15548627.2016.1208889Open reference}0.

NRF2 dysfunction has been implicated in virtually all major neurodegenerative diseases, including alzheimers, parkinsons, als, huntington-pathway, and multiple-sclerosis. In these conditions, NRF2 activity declines with aging and disease progression, leaving neurons and glia increasingly vulnerable to oxidative-stress, mitochondrial-dysfunction, and neuroinflammation ^{3Citation2016 · DOI 10.1080/15548627.2016.1208889Open reference}1^{3Citation2016 · DOI 10.1080/15548627.2016.1208889Open reference}2. Pharmacological NRF2 activators — including dimethyl fumarate (Tecfidera), already FDA-approved for MS — represent one of the most promising therapeutic strategies for neuroprotection across multiple neurodegenerative diseases ^{3Citation2016 · DOI 10.1080/15548627.2016.1208889Open reference}3^{3Citation2016 · DOI 10.1080/15548627.2016.1208889Open reference}4.

Structure

NRF2 is a 605-amino-acid Cap’n’Collar (CNC) basic leucine zipper (bZIP) transcription factor with seven functional Neh (Nrf2-ECH homology) domains:

• Neh1: Contains the CNC-bZIP domain for DNA binding and dimerization with small Maf proteins; mediates binding to ARE sequences (5′-TGACnnnGC-3′) in target gene promoters ^{3Citation2016 · DOI 10.1080/15548627.2016.1208889Open reference}5.

• Neh2: N-terminal regulatory domain containing DLG and ETGE motifs that interact with Keap1 for ubiquitin-dependent degradation. The “hinge and latch” model describes how the high-affinity ETGE and low-affinity DLG motifs bind Keap1 ^{3Citation2016 · DOI 10.1080/15548627.2016.1208889Open reference}6.

• Neh3: C-terminal transactivation domain; interacts with the chromo-ATPase/helicase DNA-binding domain (CHD6).

• Neh4 and Neh5: Transactivation domains that recruit CBP/p300 coactivators.

• Neh6: Serine-rich domain; mediates Keap1-independent degradation through β-TrCP/gsk3-beta phosphorylation.

• Neh7: Interacts with retinoic X receptor α (RXRα) to repress NRF2 activity.

Normal Function

Keap1-NRF2-ARE Signaling Pathway

The canonical NRF2 activation pathway operates as a cellular stress sensor ^{3Citation2016 · DOI 10.1080/15548627.2016.1208889Open reference}7^{3Citation2016 · DOI 10.1080/15548627.2016.1208889Open reference}8:

1. Basal state: Keap1 homodimer binds NRF2 via the DLG and ETGE motifs, serving as a substrate adapter for the Cul3-RING ubiquitin E3 ligase complex. NRF2 is continuously ubiquitinated and degraded by the ubiquitin-proteasome-system, maintaining low basal levels (half-life ~20 minutes).

2. Stress activation: Oxidative or electrophilic stress modifies reactive cysteine residues in Keap1 (especially Cys151, Cys273, Cys288), disrupting the Keap1-NRF2 interaction. NRF2 escapes degradation, accumulates, and translocates to the nucleus ^{3Citation2016 · DOI 10.1080/15548627.2016.1208889Open reference}9.

3. Transcriptional activation: Nuclear NRF2 heterodimerizes with small Maf proteins and binds to ARE sequences in target gene promoters, activating transcription of cytoprotective genes.

4. Resolution: Once stress is resolved, Keap1 shuttles to the nucleus to retrieve NRF2 and restore basal activity levels.

Key NRF2 Target Genes

NRF2 drives expression of a comprehensive cytoprotective program ^{4The emerging role of Nrf2 in mitochondrial function2015 · Free Radical Biology and Medicine · DOI 10.1016/j.freeradbiomed.2015.04.036Open reference}0^{4The emerging role of Nrf2 in mitochondrial function2015 · Free Radical Biology and Medicine · DOI 10.1016/j.freeradbiomed.2015.04.036Open reference}1:

Role in Disease

Alzheimer’s Disease

NRF2 activity is reduced in the hippocampus and cortex of AD patients, with nuclear NRF2 levels decreasing as disease severity increases ^{4The emerging role of Nrf2 in mitochondrial function2015 · Free Radical Biology and Medicine · DOI 10.1016/j.freeradbiomed.2015.04.036Open reference}2^{4The emerging role of Nrf2 in mitochondrial function2015 · Free Radical Biology and Medicine · DOI 10.1016/j.freeradbiomed.2015.04.036Open reference}3:

• Amyloid-Beta oligomers generate oxidative-stress that initially activates NRF2, but chronic exposure overwhelms the pathway, leading to NRF2 exhaustion

• Hyperphosphorylated tau[/proteins/tau-protein disrupts NRF2 nuclear import, further compromising antioxidant defenses ^{4The emerging role of Nrf2 in mitochondrial function2015 · Free Radical Biology and Medicine · DOI 10.1016/j.freeradbiomed.2015.04.036Open reference}4

• NRF2 knockout mice show exacerbated amyloid pathology, neuroinflammation, and cognitive deficits

• NRF2 activation (by sulforaphane, DMF, or genetic overexpression) ameliorates AD pathology in transgenic mouse models ^{4The emerging role of Nrf2 in mitochondrial function2015 · Free Radical Biology and Medicine · DOI 10.1016/j.freeradbiomed.2015.04.036Open reference}5^{4The emerging role of Nrf2 in mitochondrial function2015 · Free Radical Biology and Medicine · DOI 10.1016/j.freeradbiomed.2015.04.036Open reference}6

Parkinson’s Disease

• Loss of dopaminergic-neurons-snpc in the substantia-nigra is associated with high oxidative burden and diminished NRF2 signaling ^{4The emerging role of Nrf2 in mitochondrial function2015 · Free Radical Biology and Medicine · DOI 10.1016/j.freeradbiomed.2015.04.036Open reference}7

• alpha-synuclein aggregates impair NRF2 function by sequestering p62/SQSTM1, disrupting selective autophagy ^{4The emerging role of Nrf2 in mitochondrial function2015 · Free Radical Biology and Medicine · DOI 10.1016/j.freeradbiomed.2015.04.036Open reference}8

• NRF2 activators protect dopaminergic neurons in MPTP, 6-OHDA, and rotenone PD models ^{4The emerging role of Nrf2 in mitochondrial function2015 · Free Radical Biology and Medicine · DOI 10.1016/j.freeradbiomed.2015.04.036Open reference}9

• pink1-protein and ^{5UniProt: Q16236Open reference}0(/proteins/parkin)-mediated mitophagy is positively regulated by NRF2 through p62 induction

ALS

• sod1-protein mutant mice show progressive decline in NRF2 activity in spinal cord motor-neurons

• NRF2 activation delays disease onset and extends survival in SOD1-G93A mice ^{5UniProt: Q16236Open reference}1

• tdp-43 proteinopathy impairs NRF2-mediated stress response in motor neurons

Huntington’s Disease

• Mutant huntingtin protein disrupts NRF2-dependent gene expression in striatal medium-spiny-neurons

• NRF2 activation reduces mutant huntingtin aggregation and improves motor function in HD models ^{5UniProt: Q16236Open reference}2

Therapeutic Targeting

NRF2 activation is a highly active area of therapeutic development for neurodegeneration ^{5UniProt: Q16236Open reference}3^{5UniProt: Q16236Open reference}4:

Approved NRF2 Activators

• Dimethyl fumarate (DMF / Tecfidera): FDA-approved for multiple-sclerosis. Activates NRF2 by modifying Keap1 cysteine residues. Reduces neuroinflammation, enhances glutathione levels, and protects oligodendrocytes. Under investigation for AD and PD ^{5UniProt: Q16236Open reference}5^{5UniProt: Q16236Open reference}6.

• Omaveloxolone (Skyclarys): FDA-approved for friedreichs-ataxia (2023). The first NRF2 activator approved specifically for a neurodegenerative condition. Synthetic triterpenoid that potently activates NRF2 ^{5UniProt: Q16236Open reference}7.

Investigational NRF2 Activators

• Sulforaphane: Natural isothiocyanate from cruciferous vegetables; potent NRF2 activator; clinical trials in autism, AD, and schizophrenia

• Curcumin analogs: Modified curcuminoids with improved bioavailability; NRF2 activators in preclinical studies

• CDDO derivatives: Synthetic triterpenoids with NRF2-activating properties; clinical trials for various indications

Brain Atlas Resources

• Allen Human Brain Atlas: NRF2 expression search

• Allen Mouse Brain Atlas: NRF2 search

• Allen Cell Type Atlas: Transcriptomic cell type reference

• BrainSpan Developmental Transcriptome: NRF2 developmental expression

See Also

• [Index

External Links

• PubMed

Background

The study of Nrf2 (Nuclear Factor Erythroid 2 Related Factor 2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

^{5UniProt: Q16236Open reference}8: - Allen Brain Atlas ^{5UniProt: Q16236Open reference}9: - Allen Human Brain Atlas: NRF2 search ^{6Allen Brain AtlasOpen reference}0: - Allen Mouse Brain Atlas: NRF2 search ^{6Allen Brain AtlasOpen reference}1: - Allen Cell Type Atlas ^{6Allen Brain AtlasOpen reference}2: - BrainSpan Developmental Transcriptome## See Also